Canaccord Genuity maintained its Buy rating on shares of Bioventus Inc (NASDAQ:BVS), with a steady price target of $12.00. The firm focused on the company’s recent divestiture, which is expected to have a limited immediate impact on debt reduction but will streamline the company's focus on high-growth segments.
The divestiture is set to reduce approximately $20,000, which is about 5% of Bioventus's existing debt. Despite this modest debt paydown, the company will lose around 9% of its trailing twelve months (TTM) revenues and approximately 6% of its TTM adjusted EBITDA.
This move was previously discussed in August at a conference, where Bioventus indicated that the divestment would not only improve margins, as the business being divested has lower margins than the company's average but would also allow for the reallocation of resources and time to invest in high-growth areas such as the PNS and international businesses.
Canaccord Genuity views the divestiture favorably, as it aligns with Bioventus's strategy of focusing on its most impactful segments and gradually paying down its debt. Even though the debt reduction from this divestiture is described as more incremental than transformative, the firm believes it supports the company's overall trajectory towards streamlining operations and enhancing growth.
Bioventus Inc. posted a strong financial performance for the second quarter of 2024, marked by a 14% increase in organic revenue growth. The company raised its financial guidance for the year, projecting higher net sales, adjusted EBITDA, and adjusted earnings per share. This growth was primarily driven by the Surgical Solutions and Pain Treatments segments, with significant contributions from the Ultrasonics and Bone Graft Substitutes product lines, and a surge in demand for osteoarthritis treatments.
The company anticipates continued mid-single-digit growth for the Exogen business throughout the year and has updated its 2024 financial guidance, signaling confidence in its performance and market position. Plans are in place for strategic investments in medical education, commercial execution, and R&D to sustain long-term growth.
Despite an increase in adjusted total operating expenses due to higher sales commissions and a growing workforce, the International segment grew by 4%, with acceleration expected in the latter part of the year. The company's HA business, particularly the Durolane product, is successfully gaining market share as Bioventus focuses on geographical expansion and investment in high-growth potential areas.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Bioventus Inc's financial position and market performance, providing context to Canaccord Genuity's maintained Buy rating. Despite the company's recent struggles with profitability, as indicated by its negative P/E ratio of -74.31 over the last twelve months, there are signs of potential improvement. An InvestingPro Tip suggests that net income is expected to grow this year, aligning with analysts' predictions that the company will turn profitable.
Bioventus has demonstrated strong market performance, with a remarkable 262.12% price total return over the past year. This impressive growth is reflected in another InvestingPro Tip, which notes the company's high return over the last year. Currently trading at 95.12% of its 52-week high, Bioventus appears to be maintaining investor confidence despite its financial challenges.
The company's revenue growth of 5.14% over the last twelve months, coupled with a 10.32% quarterly growth, indicates a positive trajectory that could support Canaccord Genuity's optimistic outlook. Additionally, Bioventus's gross profit margin of 66.53% suggests a strong ability to control costs in its core operations, which may be further enhanced by the recent divestiture aimed at improving overall margins.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Bioventus, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.